Glioblastoma News and Research

RSS

Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.

New ultrasound technique breaches blood brain barrier to treat gliomas

In a promising sign for the potential of focused sound waves to improve care for brain tumors, UVA Health researchers have determined that tumors called gliomas may be even more receptive to targeted drug delivery than normal brain tissue.

30 Jul 2026

Researchers find potential pathway to improve glioblastoma treatment

New research published in Neuro-Oncology gives a glimpse at promising discoveries that could help shape the future of glioblastoma treatment and patient outcomes.

29 Jul 2026

Brain cancer Achilles heel revealed in the hours after surgery

Scientists in Britain and Spain have discovered critical windows after glioblastoma surgery when the brain’s defenses falter, creating a rare chance to deliver powerful treatments exactly where needed.

29 Jul 2026

New human tissue model tracks aggressive brain tumor infiltration

Glioblastoma is an aggressive brain tumor that infiltrates deep into the surrounding brain tissue. Even after surgery, tumor cells remain in the brain and the tumor recurs.

28 Jul 2026

Spermidine boosts key cellular processes linked to aging in early research

This review finds that spermidine supports autophagy, mitochondrial function, and healthspan in experimental models, while observational studies link higher dietary intake to lower mortality. However, human trials have produced limited and mixed results, leaving its clinical role in healthy aging unresolved.

23 Jul 2026

UVA researchers develop a new experimental approach to target glioblastoma

University of Virginia Comprehensive Cancer Center scientists have developed a promising new experimental approach to targeting glioblastoma, the most common and deadliest brain cancer.

22 Jul 2026

Study reveals sex-based protein differences across lung cancer types

Biological sex factors into cancer in ways you might not expect. In lung cancer, a form called squamous cell carcinoma disproportionately affects males while adenocarcinoma occurs more frequently in females.

21 Jul 2026

KAIST study opens a new avenue for treating intractable brain tumors

Researchers have uncovered a clue to why immune checkpoint inhibitors-cancer therapies that release the immune "brakes" exploited by tumors to evade attack-show limited efficacy in some brain tumors.

19 Jul 2026

Blood ketone threshold may help predict weight loss success

Achieving and sustaining a blood ketone level of 0.5 mmol/L is crucial for weight loss in ketogenic diets, offering a new approach to dietary monitoring.

16 Jul 2026

EGFR inhibitors may overcome chemotherapy resistance in glioblastoma treatment

Treating glioblastoma with a class of drugs known as EGFR inhibitors made this cancer more sensitive to chemotherapy, suggests a study in preclinical models co-led by researchers at UT Southwestern Medical Center and the University of Alabama at Birmingham.

12 Jul 2026

Experimental compound BA-101 overcomes chemotherapy resistance in glioblastoma

Scientists have identified a promising new strategy to tackle one of the biggest obstacles in treating glioblastoma, one of the most aggressive form of brain cancer: resistance to chemotherapy.

9 Jul 2026

CAR-T cell therapy shows potential to eliminate aggressive glioblastoma

A study led by a researcher based at King's College London and McMaster University in Canada reveals how CAR-T cell therapy, a treatment that engineers a patient's own immune cells to recognize and attack cancer, could be used to treat glioblastoma.

1 Jul 2026

Dual-target CAR-T therapy shows promise against aggressive brain tumors

Researchers at McMaster University have developed a new cancer immunotherapy strategy that can simultaneously attack deadly brain tumors and the immune cells that help them grow.

1 Jul 2026

Study uncovers sex-specific immune pathway driving glioblastoma growth

Researchers have identified a critical biological difference in how glioblastoma develops in male and female laboratory models, pinpointing an immune pathway that fuels tumor growth only in females.

23 Jun 2026

Sugar-coated nanoparticles extend survival in aggressive glioblastoma mouse model

Researchers at Oregon State University have potentially found a new way to treat the most aggressive form of brain cancer, glioblastoma, whose two-year survival rate is less than 30%.

23 Jun 2026

Using the mathematics of quantum mechanics to improve neuroblastoma outcomes

For a child diagnosed with neuroblastoma-the most common infant cancer, occurring when early nerve cells grow out of control-the path to treatment isn't simple.

22 Jun 2026

New CellTrap technology reveals how single immune cells attack brain tumors

Established laboratory tests mainly capture average values across many cells and show, for example, how many cancer cells survive after contact with immune cells.

18 Jun 2026

Dual-target CAR T therapy triggers broad immune response in brain cancer

Dual-target CAR T cell therapy for recurrent glioblastoma (GBM), delivered directly into the cerebrospinal fluid (CSF), triggers a broad immune response, with natural killer (NK) cell activation linked to better patient outcomes and longer overall survival.

15 Jun 2026

Major NIH grant helps establish the Oklahoma Center of ImmunoEngineering

The University of Oklahoma has received an $11.5 million award from the National Institutes of Health to establish the Oklahoma Center of ImmunoEngineering, a new research center designed to accelerate the study and treatment of diseases rooted in the immune system.

12 Jun 2026

PhoreMost announces lead oncology program and appoints Chief Medical Officer to support clinical entry

PhoreMost Limited, a biotech company focused on turning scientific breakthroughs into life-changing cancer drugs, today announced its lead program, PMC-001, a next-generation, small molecule microtubule targeting agent (MTA) for primary and secondary brain cancers.

From PhoreMost 12 Jun 2026